Biotechnology - Biotechnology, Nephrology and Hepatology


Popular Filters

1 to 25 of 32 results

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism

Further positive Ph III results for Amgen’s AMG 416 in secondary hyperparathyroidism


USA-based Amgen has released positive data from a second placebo-controlled Phase III study evaluating…

AMG 416AmgenBiotechnologyClinical researchHemodialysisNephrology and HepatologyResearchUSA

Alnylam and TAP collaborate on ALN-AAT, for AAT deficiency-associated liver disease

Alnylam and TAP collaborate on ALN-AAT, for AAT deficiency-associated liver disease


RNAi therapeutics company Alnylam Pharmaceuticals and The Alpha-1 Project (TAP), the venture philanthropy…

ALN-AATAlnylam PharmaceuticalsBiotechnologyNephrology and HepatologyRegulationResearchThe Alpha-1 ProjectUSA

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex


German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly


The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products


US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million


San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

Evolva to license EV-077 to Serodus


Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Interim results for ChemoCentryx' CCX140 fail to inspire


US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

Keryx Biopharma files for US approval of Zerenex


Keryx Biopharmaceuticals (Nasdaq: KERX) says it has submitted a New Drug Application to the US Food and…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyNorth AmericaRegulationZerenex

AstraZeneca to fork out $815 million for rights to anemia drug candidate


In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

UK's NICE recommends new therapy for liver cancer patients


UK specialist health care company BTG (LSE: BTG) says that the UK's National Institute for Health and…

BiotechnologyBTGEuropeNephrology and HepatologyNordionOncologyRegulation

Ocera Thera and Tranzyme complete merger


US clinical-stage biopharma firm Ocera Therapeutics and Tranzyme (Nasdaq: TZYM) have completed their…

BiotechnologyMergers & AcquisitionsNephrology and HepatologyOcera TherapeuticsOCR-002Tranzyme

Routine cinacalcet for end stage kidney disease not warranted


Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and…

AmgenBiotechnologycinacalcetNephrology and HepatologyPharmaceuticalResearchSensipar

Positive EU regulatory news for Alexza and Ferrer, but not Gentium


USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) and Spanish partner Grupo Ferrer Internacional have received…

AdasuveAlexza PharmaceuticalBiotechnologydefibrotideEuropeFerrer InternacionalGentiumNephrology and HepatologyNeurologicalPharmaceuticalRegulation

Keryx Biopharma rockets on new Zerenex data and plans to file for approval


USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

Amgen and KPCB to create Atara Biotherapeutics; Banner Pharmacaps changes hands


The world's largest biotech firm Amgen (Nasdaq: AMGN) and venture capital group Kleiner Perkins Caufield…

AmgenAtara BiotherapeuticsBanner PharmacapsBiotechnologyLicensingMergers & AcquisitionsNephrology and HepatologyOncologyPatheonPharmaceuticalProduction

FDA extends PDUFA date for Biogen Idec's MS drug BG-12; Abbott and Reata's bardoxolone stalled


Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell 3% to $149.50 in premarket trading yesterday,…

Abbott LaboratoriesbardoxoloneBG-12Biogen IdecBiotechnologyDiabetesNephrology and HepatologyNeurologicalNorth AmericaPharmaceuticalReata PharmaceuticalsRegulationResearch

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa


More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa…

BiotechnologyDiabetesGenericsMarkets & MarketingNephrology and Hepatology

AVEO and Astellas file NDA for tivozanib in kidney cancer


USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients


Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

Erythropoietin market in Japan to reach $1.54 billion by 2015


The erythropoietin market in Japan is forecast to reach $1.54 billion by 2015 by analysts at TechNavio.…

Asia-PacificBiotechnologyGenericsMarkets & MarketingNephrology and HepatologyPatents

Affymax and Takeda get special Medicare code for Omontys


USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

Amgen to snap up KAI Pharma for $315 million


In a second acquisition announced so far this year, global biotech leader Amgen (Nasdaq: AMGN) said yesterday…

AmgenBiotechnologyKAI PharmaceuticalsMergers & AcquisitionsNephrology and Hepatology

Promethera raises 23.6 million euros, with backers including Shire and Boehringer


Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

1 to 25 of 32 results



Back to top